PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, announced today that shareholders approved all proposals put forward by the Board of Directors at the Company's fifth annual General Meeting with a large majority. The meeting took place at the Chollerhalle in Zug, where a total of 26,780,855 shares with voting rights were represented, corresponding to 80.85% of the issued registered shares.
All six members of the Board of Directors proposed for re-election were appointed for a term ending at the conclusion of the next annual General Meeting 2027. Peter Wilden was re-elected as Chair of the Board of Directors, and Philippe Weber and Peter Wilden were each individually re-elected as members of the Remuneration and Nomination Committee for a term ending at the conclusion of the next annual General Meeting 2027.
Further proposals approved at the AGM 2026 included the re-election of the Statutory Auditors and the Independent Proxy, as well as the approval of the maximum aggregate amount of compensation for the Board of Directors and Executive Committee. Shareholders also granted discharge to all members of the Board of Directors and Executive Committee for their activities in the financial year 2025. Additionally, shareholders approved the Management Report, Statutory Financial Statements, Consolidated Financial Statements, and the report on non-financial matters for the financial year 2025, as well as the Remuneration Report 2025 in a separate consultative vote.
The approval of these proposals underscores shareholder confidence in PolyPeptide's governance and strategic direction. As a specialized CDMO, PolyPeptide plays a crucial role in the development and manufacturing of peptide-based therapies, which are increasingly important in addressing metabolic diseases, including GLP-1 agonists. The company's global network of six GMP-certified facilities in Europe, the U.S., and India positions it to meet growing demand from pharmaceutical and biotech clients.
The minutes of the AGM 2026 will be available within 15 days on the Company's website. The next annual General Meeting 2027 will be held on 7 April 2027. For more information about PolyPeptide and its services, visit polypeptide.com or follow the company on LinkedIn.
